Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

atai Life Sciences amends loan agreement to support IntelGenx upgrade to TSX

atai Life Sciences (NASDAQ;ATAI) amended a loan agreement with IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) to support IntelGenx’s conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock...

September 15, 2021

Developments

Cognetivity’s ICA to be deployed in world-leading UK dementia care practice

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF) agreed with Loveday & Co. to deploy the Integrated Cognitive Assessment (ICA) in the specialist dementia and senior care provider’s practice. Loveday is the only...

September 14, 2021

Developments

PharmaJet to deliver Scancell COVID-19 DNA vaccines

Closely held PharmaJet was selected by partner, Scancell, to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2, using the PharmaJet Tropis and PharmaJet Stratis Needle-free injection systems. ...

September 14, 2021

Developments

Hepion Pharma moving into Phase 2b NASH trial after additional positive Phase 2a data

Hepion Pharmaceuticals (NASDAQ:HEPA) is initiating a Phase 2b clinical trial after releasing additional positive efficacy data from its Phase 2a AMBITION trial with CRV431 for the treatment of non-alcoholic...

September 13, 2021

Developments

IntelGenx partner launches RIZAPORT for acute migraine in Spain

IntelGenx’s (TSXV:IGX; OTCQB:IGXT) commercialization partner in the EU, Exeltis Healthcare, launched RIZAPORT, a unique treatment of acute migraine, in Spain. RIZAPORT is based on IntelGenx’s...

September 8, 2021

Developments

111, Inc. in $10-million share repurchase program

The board of Shanghai-based 111, Inc. (NASDAQ:YI) authorized a share repurchase program of up to $10-million of the company’s Class A ordinary shares in the form of American depositary shares in the next 12 months. The...

September 7, 2021

Developments

IntelGenx ships CBD filmstrips to Heritage Cannabis to support market launch

IntelGenx (TSXV:IGX; OTCQB:IGXT) completed an initial shipment of CBD Filmstrips in support of Heritage Cannabis Holdings’ (CSE:CANN) Canadian market launch of its “CB4 Control” branded product. The CBD Filmstrips were...

August 31, 2021

Developments

Sigyn Therapeutics featured on NPR’s Tech Nation

Jim Joyce, CEO of Sigyn Therapeutics (OTC Markets:SIGY) was interviewed by National Public Radio’s Tech Nation about the treatment of life-threatening inflammatory conditions precipitated by cytokine storm syndrome. In...

August 30, 2021

Developments

111 Inc. Q2 net revenue jumps 86.5%

Shanghai-based 111 Inc. reported net revenue rose 86.5% for the second quarter to $468.4-million (RMB3.0-billion). Mr. Junling Liu, co-founder, chairman, and CEO of 111, said the second quarter represented another...

August 27, 2021

Developments

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Raymond James gave winning marks to Profound Medical‘s (NASDAQ:PROF; TSX:PRN) TULSA-PRO device, compared with the Focal One HIFU device from France’s EDAP TMS SA (NASDAQ:EDAP), in a head-to-head comparison study...

August 26, 2021

Developments

FSD Pharma to acquire Lucid Psycheceuticals

FSD Pharma (NASDAQ:HUGE; CSE:HUGE; FRA:0K9A) agreed to acquire all the shares of closely-held, Lucid Psycheceuticals, for approximately $9-million in FSD Pharma stock. “Lucid has successfully developed a strong...

August 25, 2021

Developments

FDA clears Vifor, Cara pruritus injection associated with CKD

The FDA approved an NDA from Vifor Pharma and Cara Therapeutics (NASDAQ:CARA) for their KORSUVA injection for the treatment of moderate-to-severe pruritus (itch) associated with chronic kidney disease in adults...

August 24, 2021

Developments

Pfizer to acquire Trillium Therapeutics to expand immuno-oncology therapies

Pfizer (NYSE:PFE) entered into a definitive agreement to acquire Trillium Therapeutics (NASDAQ, TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. ...

August 23, 2021

Developments

PharmaJet needle free system cleared for first plasmid DNA COVID-19 vaccine

Closely-held PharmaJet announced that its partner, Zydus Cadila, has received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first plasmid DNA vaccine for...

August 23, 2021

Developments

111, Inc. deepens partnership with Bayer

111, Inc. (NASDAQ:YI) has expanded its existing partnership with Bayer Healthcare in China. The original partnership was signed in September 2020 and involved collaborating on drug commercialization initiatives in China...

August 16, 2021

Developments

Tryp Therapeutics, Calvert Labs in pact to study psilocybin formulations

Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) agreed with Calvert Labs, an Altasciences company, to design and execute exploratory studies related to Tryp’s psilocybin-for-neuropsychiatric disorders (PFN) program. The...

August 10, 2021

Developments

Altamira reports protective effects of Bentrio nasal spray against Influenza A virus

Altamira Therapeutics (NASDAQ:CYTO) announced positive outcomes from testing Bentrio for prophylactic or therapeutic use in influenza A virus infection. Bentrio is a drug-free nasal spray being developed by the...

August 6, 2021

Developments

Profound Medical posts sequential 145% jump in Q2 recurring revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) reported a 145% increase in recurring revenue for the second quarter, compared with the first quarter of 2021. Total revenue, including capital sales outside of the U.S...

August 5, 2021

Developments

111, Inc. in strategic pact with Suzhou Zelgen to develop platform for liver cancer patients in China

111, Inc. (NASDAQ: YI) announced a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals (688266.SH), an innovative drug R&D and production company. The agreement will allow 111, a leading tech...

August 3, 2021

Developments

CymaBay in $100-million non-dilutive financing for Phase 3 trial

CymaBay Therapeutics (NASDAQ:CBAY) announced a $100-million non-dilutive financing transaction with Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the...

August 2, 2021

Developments

Deep Genomics raises $180-million (U.S.) to develop drugs discovered by AI

University of Toronto spinout, Deep Genomics, raised $180-million (U.S.) led by Softbank’s Vision Fund 2 to bankroll its efforts to discover and develop drugs using artificial intelligence. The funding group included...

July 28, 2021

Developments

Talkiatry completes $20-million Series A funding

Closely held Talkiatry, a provider of accessible in-network psychiatric care, completed its $20-million a Series A funding, of which $15-million was led by Left Lane Capital, with participation from Dr. Richard Park...

July 28, 2021

Subscribe